A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
about
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma.Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
P2860
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
description
1988 nî lūn-bûn
@nan
1988 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@ast
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@en
type
label
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@ast
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@en
prefLabel
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@ast
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@en
P2093
P1476
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
@en
P2093
P304
P356
10.1016/0277-5379(88)90299-4
P577
1988-04-01T00:00:00Z